Cytoreductive surgery and HIPEC (hyperthermic intraperitoneal chemotherapy) in combined treatment of ovarian cancer: time for the beginning of personalized therapy?

Publié en ligne: 28 sept. 2019

Pages: 154 - 159

Reçu: 08 janv. 2019

Accepté: 27 mars 2019

DOI: https://doi.org/10.2478/cipms-2019-0028

Mots clés

ovarian cancer, peritoneal carcinomatosis, cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, p53, BRCA 1

© 2019 Roman Yarema et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.